Results 211 to 220 of about 1,988,593 (307)

Effects of proton therapy on the tumor immune system and clinical implications: A review

Precision Radiation Oncology, EarlyView.
Proton therapy is a novel radiotherapy technique. We review four aspects of proton therapy: application in various tumors, effects on the tumor immune system, combination with other therapies, and future challenges. By presenting these aspects in this review, we aim to inspire clinical interventions.
Rundong Liu, Mei Tao, Min Fu, Yingjia Hu, Zhen Tao, Guangyuan Hu   +5 more
wiley   +1 more source

Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post-Biopsy Bleeding. [PDF]

DEN Open
Kosaka Y, Yamane H, Nakanishi H, Takigawa N.   +3 more
europepmc   +1 more source

Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 448-459, March 2025.
Abstract Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease‐induced and treatment‐related cytopenias.
Neha Thakre, Corinna Maier, Jiuhong Zha, Benjamin Engelhardt, Johannes E. Wolff, Sven Mensing   +5 more
wiley   +1 more source

Roth Spots As the Initial Manifestation of Accelerated-Phase Chronic Myeloid Leukemia. [PDF]

Cureus
Benchekroun M, Hamidi S, Fakhir B, Benchekroun Belabbas S, Cherkaoui LO.   +4 more
europepmc   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms. [PDF]

Blood Cancer J
Haddad FG, Kantarjian H.
europepmc   +1 more source

Piper nigrum Has an Antitumor Effect Through Regulation of the Phosphatidylinositol 3‐Kinase Signaling Pathway in a Murine Model of Acute Myeloid Leukemia

Phytotherapy Research, EarlyView.
Overview of the antileukemic effects of Piper nigrum extract in AML. P. nigrum reduced leukemic cell proliferation and glycolytic metabolism through modulation of the PI3K/AKT/mTOR pathway. In vivo, treatment reduced leukemic burden, improved hematological parameters, prolonged survival, and modulated antitumor immune responses.
Natalia Murillo, Paola Lasso, Claudia Urueña, Susana Fiorentino   +3 more
wiley   +1 more source

Real-life data of patients with chronic myeloid leukemia in Amazonas. [PDF]

BMC Cancer
Abreu RS, Maior KS, Souza IML, Paes JF, Nascimento BEF, Santos RO, Romero NPG, Martins JP, Costa AG, Malheiro A, Martins-Filho OA, Tarragô AM, Passos LNM.   +12 more
europepmc   +1 more source

Apigenin Protects Hypertensive Intracerebral Hemorrhage by Regulating Trx1 Through Binding to PRDX2

Phytotherapy Research, EarlyView.
ABSTRACT Intracerebral hemorrhage (ICH) remains the most severe stroke subtype with high mortality and disability rates. Although apigenin has shown cerebroprotective potential in preclinical studies, its mechanism of action, particularly in hypertensive ICH, remains poorly understood.
Hao‐chen Xu, Ming Liu, Ying‐ying Sun, Jie‐Dan Ping, Qing‐hua Cui, Jing‐zhou Chen, Hao Li   +6 more
wiley   +1 more source

Clonal and genomic determinants of e1a2 <i>BCR::ABL1</i> chronic myeloid leukemia: A Fi-LMC study. [PDF]

Hemasphere
Podvin B, Nibourel O, Hayette S, Coiteux V, Kim R, Rigolot L, Dulucq S, Boudry A, Pawlak G, Lambert WC, Flandrin-Gresta P, Sloma I, Roumier C, Balsat M, Loron S, Li C, Geffroy S, Cayuela JM, Huguet F, Mahon FX, Nicolini FE, Réa D, Preudhomme C, Duployez N, Roche-Lestienne C, Fi‐LMC group.   +25 more
europepmc   +1 more source